Current Clinical Progress of PD-1/PD-L1 Immunotherapy and Potential Combination Treatment in Non–Small Cell Lung Cancer

Jia-Xin Li, MB1, Ju-Min Huang, MPhil1, Ze-Bo Jiang, MPhil1, Run-Ze Li, PhD1, Ao Sun1, Elaine Lai-Han Leung, PhD1,2, and Pei-Yu Yan, MD, PhD1

Abstract
Conventional methods in treating non–small cell lung cancer contain surgery, chemotherapy, radiotherapy, and targeted therapy, which have various defects. Recently, with the deeper research on tumor immunity, immunotherapy has made the breakthrough in the treatment of cancers. Especially developments of programmed cell death ligand-1 (PD-1/PD-L1) inhibitors bring the therapy into a new stage. This review mainly focuses on introducing existing monoclonal antibodies containing nivolumab, pembrolizumab, atezolizumab, avelumab, and durvalumab, along with 3 ordinary biomarkers such as PD-L1 expression, tumor mutation burden, and microsatellite instability. By understanding the resistance mechanism of anti-PD-1/L1 blockade, research is further improving the survival benefit and expanding the benefit population. So, PD-1/PD-L1 inhibitors begin to be combined with various therapeutic strategies clinically. Discussion and comparison of their effectiveness and safety are also comprehensively reviewed. Meanwhile, we explore the potential, the impact, and mechanisms of combining traditional Chinese medicine with immunotherapy.

Keywords
non–small cell lung cancer, immunotherapy, PD-1/PD-L1 inhibitor, biomarker, combinational therapy, Chinese herbal medicine, review

Submitted July 12, 2019; revised October 12, 2019; accepted October 29, 2019

Introduction
Lung cancer, which is the most common malignancy in the clinic, is a main cause of death worldwide. Non–small cell lung cancer (NSCLC), including squamous cell carcinoma, adenocarcinoma, and large cell carcinoma, accounts for over 85% of lung cancer cases and has attracted substantial attention as well as pharmaceutical investment.1 Nowadays, treatments of NSCLC mainly includes surgery, chemotherapy, radiotherapy (including hypofractionated or stereotactic radiotherapy), and targeted therapy (especially drugs targeting antiangiogenesis as well as the epidermal growth factor receptor [EGFR] mutations). Surgical treatment is to remove the cancerous tissue while cleaning the nearby lymph nodes, and it is only suitable for early stages. Resection rates for stages I and II range from 49% to 77%.2,3 Chemotherapy is a method of using conventional chemotherapeutic agents to increase antigenicity via immunogenic cell death of tumor cells as well as to augment antitumor immunosurveillance in the tumor microenvironment (TME), but chemotherapy also damages the normal tissue cells of the body and it has the problem of resistance.4 Similarly, radiotherapy is used as a treatment for irradiating tumors and killing tumor cells with different energy rays. Over time, stereotactic body radiation therapy (SBRT) has...
become a replacement for conventional radiotherapy, providing high doses of radiation in a small fraction with great precision. However, patients with SBRT have a higher incidence of lung toxicity than patients who have not received it. Targeted therapy that specifically targets drugs that have been identified at a carcinogenic site, allowing tumor cells to die without affecting surrounding normal tissue cells. Tyrosine kinase inhibitors (TKIs) for patients harboring epidermal growth factor receptor (EGFR) mutations have remarkably improved clinical results. Antiangiogenic agents targeting the vascular endothelial growth factor (VEGF) and VEGF receptor are also useful methods to treat NSCLC. Nevertheless, tumor-targeting therapy also has a large defect, that is, the targeted drug is often only effective for tumors at specific mutation sites, and tumor cells often have multiple mutation sites.

These above-mentioned treatments all have various disadvantages, and fewer than 5% of patients are alive 5 years later; the median survival is ~10 months. Therefore, there is a compelling need to develop therapies for enhancement of antitumor effect in those with NSCLC. In recent years, with the further study of the antitumor immunity, especially when the 2018 Nobel Prize in Physiology or Medicine Prize was awarded to American scientist James P. Allison and Japanese scientist Tasuku Honjo in recognition of their pioneering contributions made in tumor immunotherapy, a promising therapeutic approach about using immune checkpoint inhibitors (ICIs) that reverse cancer immunosuppression for the treatment of NSCLC has been discovered. Particularly successful examples are drugs that interfere with the programmed cell death-1/programmed cell death ligand-1 (PD-1/PD-L1) pathway that many tumors are able to hijack to avoid immune surveillance and editing. To be specific, PD-1 is highly expressed on the surface of activated T-cells in response to inflammation or infection, while PD-L1 is expressed on the surface of tumor cells. When PD-1 is linked to its ligand PD-L1, the complex pathway acts to suppress the immune response by inhibiting the cytotoxic T-cell response. Tumor cells can use this pathway to promote immunosuppression, thereby evading antitumor activity. PD-1 or PD-L1 inhibitors disrupt this inhibitory T-cell signaling, thereby reactivating the antitumor activity of specific cytotoxic T-cells. At the same time, cancer biomarkers are important to immunotherapy because they are characteristic biochemical indicators of tumor pathology or treatment processes that can be measured objectively and contribute to screening, diagnosis, and prediction.

Despite some success, the majority of cancer patients who receive PD-1/PD-L1 blockades will not respond, and only small proportion of patients (<30%) may have benefit from immune checkpoint monotherapy. Thus, this fact has led investigators to prioritize more efficacious combinatorial therapies. This review chiefly summarizes 5 anti-PD-1/L1 inhibitors as well as 3 main biomarkers; then we highlight the combination of PD-1/L1 inhibitors with the existing cancer treatments, including targeted therapy, chemotherapy, radiotherapy, and other immunotherapy in NSCLC due to the current limitation of monoclonal antibodies. Because some Chinese herbal formulas or single compounds can decrease the toxicity and may improve overall survival (OS), we also want to explore the effect and mechanisms of combining Chinese herbal medicines with anti-PD-1/PD-L1 antibody for NSCLC patients.

Current Clinical Available PD-1/PD-L1 Antibodies for NSCLC Therapy

Since the first immunological checkpoint inhibitor was approved by the Food and Drug Administration (FDA) for lung cancer, numerous clinical trials are underway. There are currently 5 monoclonal anti-PD-1/PD-L1 antibodies, nivolumab, pembrolizumab, atezolizumab, durvalumab, and avelumab, approved in advanced NSCLC by the US FDA. First, nivolumab is a humanized immunoglobulin (Ig) G4 PD-1 ICI antibody. It was initially approved in squamous cell lung cancer irrespective of PD-L1 expression, and the subsequent approval in non–squamous cell lung cancer was also specified. Two similar phase III trials, CheckMate-017 and CheckMate-057, comparing nivolumab against a standard second-line chemotherapy agent, docetaxel, have demonstrated the benefit of nivolumab. Second, pembrolizumab is a humanized IgG4 antibody against PD-1. It was approved in platinum-refractory advanced NSCLC by the FDA in 2015 and is the only checkpoint inhibitor currently approved for first-line advanced NSCLC. Furthermore, it was originally approved in those with high PD-L1 expression (Tumor Proportion Score ≥50%), and the FDA modified their approval for it as second-line therapy to include those with PD-L1 >1% based on the results of the KEYNOTE-001 and KEYNOTE-010 trials. In 2017, pembrolizumab plus chemotherapy such as carboplatin has been approved for the first-line treatment of metastatic/advanced non–squamous non–small lung cancer regardless of PD-L1 expression and with no EGFR or ALK genomic tumor aberrations. Third, atezolizumab is a humanized engineered IgG1 monoclonal antibody targeting PD-L1, being the first and currently the only anti-PD-L1 antibody approved in NSCLC. It is efficient and safe for second-line treatment of both advanced squamous and adenocarcinoma histologies irrespective of PD-L1 status. The OAK trial highlighted the efficacy of atezolizumab in second-line treatment of NSCLC, suggesting that there would be an interest of using this anti-PD-L1 inhibitor in postprogression prolongation of survival. Moreover, durvalumab, as a humanized IgG1 anti-PD-L1 antibody, is still in ongoing studies in the first-line metastatic NSCLC therapy. One of the trials, PACIFIC, exhibited positive progression-free survival (PFS) results,
demonstrating that it can be used for maintenance treatment of patients with locally advanced (stage III) resectable NSCLC without disease progression following platinum-based chemoradiation therapy.\textsuperscript{14,17} Last but not least, avelumab is a fully human IgG1 antibody, also still in ongoing studies. Avelumab monotherapy is currently being compared with docetaxel as first-line therapy in patients with PD-L1 expressing in the phase III JAVELIN Lung 100 trial and as second-line therapy in the phase III JAVELIN Lung 200 trial, showing improved OS.\textsuperscript{18}

As we all know, traditional chemotherapeutics usually induce adverse events (AEs) such as fatigue, cough, and diarrhea, while anti-PD-1/L1 inhibitors have less. However, when using this immunotherapy, immune-related AEs including colitis, pneumonitis, hepatitis, endocrinopathy, skin toxicity, and arthralgia are commonly encountered. Corticosteroids are the mainstay for management of immune-related AEs, and the use of them does not necessarily change the efficiency of anti-PD-1/L1 inhibitor therapy.\textsuperscript{19,20} Currently, a large number of completed or ongoing clinical trials are carried out across the world for evaluating the efficacy and safety of multiple ICIs as monotherapy, and partial results are presented in Table 1.\textsuperscript{15,17,21-27} Thus, from the results, we can find that compared with regular chemical agents, anti-PD-1/PD-L1 agents have higher response rates as well as improved PFS and OS. Furthermore, patients who were treated with atezolizumab had much higher median OS than with atezolizumab, pembrolizumab, and nivolumab. PFS is generally positively correlated with OS and has been used as an alternative indicator of OS in some studies. From those clinical trials referred to in Table 1, patients treated with durvalumab had higher PFS than with pembrolizumab, showing the good effect in durvalumab. At the same time, the frequency of AEs of grade 3 or 4 about ICIs is mostly much lower than chemical agents (Table 1).

**Current Available Valid Biomarkers to Predict Responses to PD-1/PD-L1 Therapy and Their Limitations**

Despite the success of ICIs, not all patients have long-term responses and the response varies between different patients. Considering irreversible autoimmune toxicities, accurate patient selection will become more crucial. So there remains an urgent need to find reliable biomarkers to help determine patients who will benefit from ICIs. Nowadays PD-L1 expression by immunohistochemistry (IHC), overall tumor mutational burden (TMB) along with microsatellite instability (MSI) have emerged as the 3 most commonly used clinical biomarkers.

**PD-L1 Expression by Immunohistochemistry**

It is well known that PD-L1 expression on tumor cells predicts responsiveness to PD-1 inhibitors, and overexpression of it by IHC staining has been linked with higher response rates and better results. Hence, we can conclude that the higher the expression of PD-L1 on tumor cells, the better the curative effect is, which can guide clinical decision-making. Currently, 5 clones including 22C3, 28-8, SP142, SP263, and 73-10 are being used for PD-L1 IHC testing (Table 2).

The Dako 22C3 pharmDx is the only IHC kit assay that has obtained “companion” diagnostic status by the US FDA for the therapeutic method with pembrolizumab.\textsuperscript{28} Meanwhile, the Dako 28-8 pharmDx has gained the European Conformity–mark certification. It also gains the US FDA approval as a “complementary” diagnostic tool for the use of nivolumab.\textsuperscript{29} At the same time, the Ventana SP142 assay is CE-marked and is approved as “complementary” diagnostic instrument by the US FDA for atezolizumab.\textsuperscript{30} Furthermore, the Ventana SP263 assay has also gained the CE certification and US FDA “complementary” test only for patients with urothelial carcinoma who can get benefit from durvalumab treatment.\textsuperscript{31,32} Finally, the Dako 73-10 assay is commercialized to support avelumab therapy, and it is still in development.\textsuperscript{33} All indications, assessment conditions, and PD-L1 positivity criteria are exhibited in detail in Table 2.

Each PD-L1 diagnostic testing assay uses its own platform, antibody, custom reagents, and scoring criteria to calculate Tumor Proportion Score on tumor cells. Meanwhile, each antibody binds to a specific epitope, and each assay has a unique cutoff to forecast the drug response, indicating that the interchangeability of assays might be limited. Honestly speaking, there is no gold standard assay that can precisely predict PD-1 blockade response. Thus, several cross-validation studies such as the Blueprint project are ongoing, and they will be key to achieve standardization among different IHC assays. Although it remains a major challenge, it is pivotally important to assist clinicians to select the best treatment options for patients.

**Overall Tumor Mutational Burden**

Tumor mutation burden is defined as the total number of detected errors in somatic gene coding, base substitution, gene insertion, or deletion per million bases. It is a quantitative biomarker that reflects the total number of mutations carried by tumor cells. Nonsynonymous somatic mutations change the amino acid sequence of proteins that are encoded by affected genes, forming neoantigens that can help the immune system to recognize tumors and stimulate the increase in the number of antitumor T-cells as well as the ability of antitumor response.\textsuperscript{36-38} TMB is assayed for FoundationOne samples, and results are listed as follows: TMB-low corresponds to equal or less than 5 mutations per megabase, while TMB-high corresponds to equal or greater than 20 mutations per megabase.\textsuperscript{39}

In several clinical trials with PD-1/L1 inhibitors, data about the potential of TMB have been assessed by whole...
| Therapeutic Antibody | Trial | Phase | Sample Size (n) | Patient Population | Treatment Arms | Efficacy Endpoint(s) | Grade 3 or 4 Adverse Events | Reference | Other Phase III or IV Clinical Trials of Each Antibody |
|----------------------|-------|-------|-----------------|--------------------|----------------|---------------------|----------------------------|-----------|------------------------------------------------------|
| Nivolumab (anti-PD-1) | CheckMate-017 (NCT01642004) | III | 272 | Previously treated metastatic squamous NSCLC | Nivolumab versus docetaxel | Median OS 9.2 months versus 6.0 months; HR = 0.59; P < .001 | 7% versus 55% | 21 | NCT02041533 |
| | CheckMate-057 (NCT01673867) | III | 582 | Previously treated metastatic nonsquamous NSCLC | Nivolumab versus docetaxel | Median OS 12.2 months versus 9.4 months; HR = 0.73; P = .002 | 10% versus 54% | 22 | |
| Pembrolizumab (anti-PD-1) | KEYNOTE-010 (NCT01905657) | II/III | 1034 | Previously treated, PD-L1 positive, metastatic NSCLC | Pembrolizumab 2 mg/kg versus pembrolizumab 10 mg/kg versus docetaxel | Median OS (2 mg/kg) 10.4 months versus 8.5 months; HR = 0.71; P = .0008 | 13% versus 35%; 16% versus 35% | 15 | NCT03134456 NCT02041533 NCT02864394 |
| | KEYNOTE-021 (NCT02039674) | II | 120 | Previously untreated metastatic NSCLC | Pembrolizumab + carboplatin + pemetrexed versus carboplatin + pemetrexed | ORR 55% versus 29%; median PFS 13 months versus 8.9 months; HR = 0.53; P = .01 | 39% versus 26% | 23 | |
| | KEYNOTE-024 (NCT02142738) | III | 305 | Previously untreated, PD-L1–positive, metastatic NSCLC | Pembrolizumab versus platinum-based chemotherapy | Median PFS 10.3 months versus 6.0 months; HR = 0.5; P < .001 | 26.6% versus 53.3% | 24 | |
| Atezolizumab (anti-PD-L1) | OAK (NCT02008227) | III | 850 | Previously treated metastatic NSCLC | Atezolizumab versus docetaxel | Median OS 13.8 months versus 9.6 months; HR = 0.73; P = .0003 | 15% versus 43% | 25 | NCT02813785 NCT02367781 NCT02409372 NCT02775435 NCT02576680 |
| | IMpower150 (NCT02366143) | III | 1202 | Previously untreated metastatic NSCLC | Atezolizumab + bevacizumab + CP versus bevacizumab + CP | Median PFS 8.3 months versus 6.8 months; HR = 0.62; P < .0001 | 25% versus 19% | 26 | |
| Durvalumab (anti-PD-L1) | PACIFIC (NCT02125461) | III | 713 | Locally advanced unresectable NSCLC, after chemoradiotherapy | Durvalumab versus placebo | Median PFS 16.8 months versus 5.6 months; HR = 0.52; P < .001 | 29.9% versus 26.1% | 17 | NCT02352948 NCT02009342 NCT02486718 NCT02367794 NCT03191786 NCT02453282 NCT02775435 NCT02657434 NCT03456063 |
| Avelumab (anti-PD-L1) | JAVELIN Lung 200 (NCT02395172) | III | 792 | Previously treated, PD-L1–positive, metastatic NSCLC | Avelumab versus docetaxel | Median OS 11.4 months versus 10.3 months; HR = 0.90; 1-sided P = .16 | 10% versus 49% | 27 | NCT02576574 |

Abbreviations: CP, carboplatin + paclitaxel; HR, hazard ratio; NSCLC, non–small cell lung cancer; ORR, objective response rate; OS, overall survival; PFS, progression-free survival.
exome sequencing traditionally. For the first time, Rizvi et al reported that higher mutation load was associated with longer PFS, improved objective response, and durable clinical benefit in advanced NSCLC patients treated with pembrolizumab.40 Similarly, in the randomized phase III trial (CheckMate-026), which compared nivolumab with chemotherapy in first-line NSCLC, results showed that patients with high mutational burden had higher objective response rate (ORR) and longer PFS.41

However, at present, whole exome sequencing is not widely available because of its costly and time-consuming characteristic.14 Although TMB is an intrinsic objective measurement of tumor, the intratumoral heterogeneity and dynamic change over time make it imperfect. Sometimes patients derive benefit despite “low” mutational burden, while many patients do not benefit despite “high” mutational burden.41 In addition, because of different techniques used to measure TMB, it is necessary to standardize assay methods.

Microsatellite Instability

Microsatellites are tandem repeats of units of 1 to 6 base pairs that are widely found in the genome. In the entire genome of the tumor, there are some microsatellites with many small genetic mutations, which means deficient DNA mismatch repair, resulting in some microsatellites being unstable. This phenomenon is MSI, and tumors can be further developed through the MSI pathway due to mismatched gene repair defects.42 MSI testing has been widely used in patients with colorectal cancer, and exploration in other tumors continues. MSI may also play a role in endometrial, ovarian, skin, brain, and upper gastrointestinal tumors.

Fluorescent multiplex polymerase chain reaction, genome- or exome-wide sequencing, next-generation sequencing, and IHC for mismatch repair proteins are used for testing MSI.43 The 1997 National Cancer Institute consensus meeting advised to test a core panel of 5 markers: BAT26, BAT25, D5S346, D2S123, and D17S250. At the same time, the MSI-high was defined in the rule about there were over 30% of the markers showing instability in other marker groups or 2 or more of the 5 markers of the core team showing instability.44

Colorectal cancer is a relatively mature disease in MSI research. In comparison to patients having non-MSI colorectal cancers, especially when the tumors are at the early stage, we can know that patients with high MSI have more favorable survival and the survival advantage of MSI gradually weakens as the tumor stage advances.45

In any case, the purpose of “precise” medical treatment is to accurately find the cause of the disease and the target of treatment. MSI testing effectively achieves accurate medical treatment for specific types of cancer patients and improves the cure rate.

To sum up, in addition to the 3 biomarkers described above, recent studies have identified several potential biomarkers such as lymphocyte activation gene-3 (LAG-3), T-cell immunoglobulin and mucin domain–containing-3 (TIM-3), TIGIT, tumor infiltrating lymphocyte,46 and so forth. In general, it is obvious that one single biomarker cannot be used to predict the benefit of immunotherapy completely. Further work needs to be carried out to explore more biomarkers and understand their mechanisms.

Classical Drug-Resistant Mechanisms of Anti-PD-1/L1 Blockades

In 2016, immunotherapy was named the largest scientific breakthrough in the world by Science magazine in the United States. PD-1/PD-L1 monoclonal antibodies have successfully subverted traditional anticancer patterns. However, not all
patients benefit from it, or they do not work at all, or they can only maintain a short-term effect mainly because of resistance. Thus, it is urgent for us to understand mechanisms of the resistance to PD-1/L1 inhibitors.

Ascierto et al found that the LAMA3 gene expression activity of tumors that were ineffective against PD-1 immunotherapy was increased by about 2000-fold, and the activity of the CXCR2 gene was also increased 4-fold through sequencing the entire exome. In another study, it has been shown that substances produced by CXCR2 inhibited T-cell function, while T-cells were major anticancer immune cells. The team of Professor Antoni Ribas explored the effect of JAK1/JAK2 gene function loss on the body’s immune antitumor response from in vitro cell experiments. Results indicated that the JAK1/JAK2 gene mutation directly led to the insensitivity of tumor cells to the killing effect of interferon, thereby promoting the resistance of tumor cells to PD-1 inhibitors. Similarly, the β-2 microglobulin gene (B2M), as a component of the major histocompatibility complex (MHC)-I molecule, played an important role in the immunogenic antigen presentation process. Mutations in the B2M gene might block CD8 T-cell recognition and were also the cause of anti-PD-1 resistance.

In addition to classical mechanisms such as neoantigen loss, and which have referred to above, HLA loss, TGF-β overexpression, along with increased TIM-3, TIGIT, and LAG-3 expression are related to resistance mechanism. More intriguingly, the research team at the University of Pennsylvania, through careful and rigorous work, discovered that some cancer patients were not sensitive to PD-1/PD-L1 inhibitors for the simple reason that their tumors were too big. The larger the tumor was, the more Ki-67-positive killer T-cells would exist in the blood, which induced the resistance.

In short, PD-1 antibody can only block the “hole” of PD-1. After that, the tumor will evade the immune system by other means. So, there are many limitations to apply PD-1/PD-L1 monoclonal antibodies for curing NSCLC. What we need to do now is to chase and intercept the roads at various intersections.

**Clinical Combination Strategies to Treat NSCLC**

There is a large consensus among doctors and researchers that both PD-1 and PD-L1 inhibitors are only approximately 20% effective in treating lung cancer. Therefore, in order to expand the beneficiary population, combination therapy is a major trend. Not only can the combination of different treatments produce a large antitumor synergy, but also it is able to reduce the dosage of each treatment as well as to avoid the emergence of drug resistance. Promising clinical and preclinical evidence for combined therapy in NSCLC has been reported (Table 3).

**Combining PD-1/L1 Inhibitors With Radiotherapy**

In the past, when NSCLC patients were unable to undergo surgical resection of tumor lesions, segmental radiation therapy was performed. With the development of new radiotherapy techniques, SBRT and stereotactic ablative radiotherapy (SABR) technology appear with characteristics of high precision and high doses of radiation. Studies have found that SBRT can induce the expression of MHC-I, inflammatory factors, costimulatory molecules, heat-shock proteins, immunoregulatory factors, and cell adhesion molecules, which results in promoting antigen presentation and enhancing the immune system’s response to tumors. During radiotherapy, immunotherapy can also upregulate the immune system and increase the interaction of cytotoxic lymphocytes (CTL) with cancer cells. Thus, radiotherapy has become one of the ideal options for synergistic effects in combination with PD-1/PD-L1 blockades.

The method of combining SABR with PD-1 inhibitors can make the original tumor almost completely disappear. At the same time, the distant lymph nodes and metastases also disappear. This phenomenon is called the “abscopal effect,” which explains the rationale behind their usage in brain metastasis. Currently, in the treatment of NSCLC, clinical trials evaluating the enhanced effect of radiotherapy on immunotherapy are underway (Table 3). Results show that combination of immunotherapy with radiotherapy has improved ORR, PFS, and OS compared with ICIs alone. However, a higher frequency of pulmonary toxicity exists in combination therapy.

**Combining PD-1/L1 Inhibitors With Chemotherapy**

Current chemotherapeutic agents such as cisplatin, carboplatin, taxanes, and pemetrexed are able to increase antitumor immune responses by a variety of mechanisms. Chemotherapy enhances CD8+ T-cells, mutational load, neoantigen heterogeneity, the maturation of APC, and a higher PD-L1 expression on tumor cells, augmenting tumor antigen presentation via immunogenic cell death of tumor cells and the MHC class I. At the same time, it downregulates immunosuppressive cells including CD4, CD25, and regulatory T-cells in the TME.

Currently, there are limited data on clinical trials of PD-1/PD-L1 antibody combined with chemotherapeutic drugs in the treatment of NSCLC. For instance, the KEYNOTE-021 study was a phase II research studying the activity of pembrolizumab with carboplatin and paclitaxel or platinum-doublet chemotherapy alone on 123 untreated patients with stage III B or IV non–squamous cell NSCLC. Results showed that the ORR of the combination therapy group and the chemotherapy-alone group were 55% and
29%, respectively ($P = .0016$); the median PFS was significantly prolonged in the combination group (13.0 months vs 8.9 months; hazard ratio [HR] = 0.53, $P = .010$). Referring to the adverse effects, in the combination treatment group, 39% of patients had grade 3 or higher AEs, while in the chemotherapy-alone group, 26% of patients had.23 Similarly, in a clinical phase I study of nivolumab and 3 platinum-based chemotherapy drugs (CheckMate012), 56 stage IIIB or IV NSCLC patients were enrolled. Grouped by tumor histological types, patients received different doses of nivolumab in combination with gemcitabine-cisplatin (squamous cell carcinoma), pemetrexed-cisplatin (non–squamous cell carcinoma), and paclitaxel-carboplatin (both histologies). In the group of nivolumab (10 mg/kg) combined with PT-DC, the OS time was 11.6 to 19.2 months, which was significantly longer than that of the platinum monotherapy group ($P < .01$). There was also a significant prolongation of OS in nivolumab (5 mg/kg) combined with paclitaxel-carboplatin. Among them, 45% of patients had a grade 3/4 treatment-related adverse reaction.67 In addition, the combinations of atezolizumab or durvalumab with different chemotherapy have also been tested, exhibiting improved ORR and more severe treatment-related AEs.68,69

In a word, combining chemotherapy with ICIs has a stronger improvement in outcomes for advanced NSCLC patients than using ICIs alone, but adverse side effects are much more serious. It is worth noting that the use of hormones before chemotherapy has become a standardized treatment for alleviating adverse reactions such as nausea and vomiting, but the use of hormones may prevent ICIs from functioning.70 Therefore, the treatment of adverse reactions is a major challenge in the future.

**Combining PD-1/L1 Inhibitors With Targeted Therapy**

Although targeted drug therapy takes effect rapidly, it inevitably produces resistance; immunotherapy, such as PD-1/ PD-L1 inhibitors, has a slow onset, but it can play a long-lasting role due to the generation of memory cells. Hence, targeted therapies for tumor angiogenesis and intrinsic driver genes in combination with immunotherapy may be a

---

**Table 3. Ongoing Combination PD-1/L1 Trials in NSCLC.**

| Other Strategy With PD-1/L1 Inhibitors | References |
|---------------------------------------|------------|
| SBRT (stereotactic body radiation therapy) | NCT02888743, NCT02407171, NCT02608385, NCT02400814, NCT02444741, NCT02831933, NCT03004183, NCT02492568, NCT02904954, NCT02599454, NCT03055890, NCT03110978, NCT03050554 |
| Chemotherapy | Phase 1: NCT01840579, NCT02998857, NCT02451930, NCT01454102, NCT03064854, NCT02309177 |
| EGFR-TKIs | Phase 1/2 or 2: NCT02382406, NCT02422381, NCT02733250, NCT02574078, NCT02039674, NCT01903993, NCT02250326, NCT02574598, NCT02581943, NCT02591615, NCT02684461, NCT02716038, NCT02967133, NCT02944396, NCT03041181, NCT03057106, NCT03081689, NCT03083808 |
| VEGF-antiangiogenic drugs | Phase 3: NCT02477826, NCT03134872, NCT02367781, NCT02578680, NCT02657434, NCT02775435, NCT02864251, NCT2008227, NCT02367794, NCT02813785, NCT02366143, NCT03117049, NCT02013219, NCT01998126, NCT02088112, NCT02364609, NCT02947836, NCT02143466, NCT02454933, NCT02630186, NCT02924233, NCT02323126, NCT02574078, NCT01454102, NCT02900664 |
| CTLA-4 inhibitors | Tremelimumab (Phase 3): NCT02352948, NCT02453282, NCT02542293 |
| Anti-LAG-3 antibody | NCT01968109 |
| Anti-TIM-3 antibody | NCT02608268 |
| IDO1 inhibitors | NCT02327078, NCT02318277, NCT02298153 |

**Abbreviation:** NSCLC, non–small cell lung cancer.
direction for the treatment of NSCLC with clear genetic mutations.

Epidermal growth factor receptor is the most common driver gene in NSCLC, and around 50% of Asian NSCLC patients, especially those with lung adenocarcinoma, have mutations in the EGFR gene. EGFR gene mutation is able to upregulate the expression of PD-L1 in tumor cells; EGFR-TKI can downregulate the expression of PD-L1 by inhibiting the signaling pathway of nuclear transcription factor-κB (NF-κB). Chen et al found that PD-1/L1 inhibitors can significantly reduce the viability of H1975 cells that are resistant to gefitinib, suggesting that immunotherapy can significantly reduce the viability of NSCLC (Table 3). EGFR gene mutation is a driver gene in NSCLC, and around 50% of Asian NSCLC patients are EGFR-mutant, especially those with NSCLC who are EGFR-mutant, with NSCLC who had not accepted immunotherapy before enrollment. A new treatment option for those patients with negative PFS rate of 47%. Of the 20 patients with erlotinib-acquired resistance, 3 (15%) had partial tumor remission and 9 (45%) had stable response. The above-mentioned interim data indicate that nivolumab combined with erlotinib can provide sustained and safe clinical benefit for patients with NSCLC who are EGFR-mutant, especially those with TKI resistance.

The growth and metastasis of tumors are inseparable from their angiogenesis. The regulatory molecules that mediate tumor angiogenesis are mainly VEGF, platelet-derived growth factor, and fibroblast growth factor. The VEGF pathway not only acts on the vascularization process of the tumor but also mediates the inhibitory immune microenvironment, thereby allowing tumor cells to escape immune surveillance. This, therefore, provides a theoretical basis for the combination of checkpoint inhibitors and antiangiogenic drugs. Researchers recently did a phase III IMPower150 study of bevacizumab (monoclonal antibody against VEGF) and atezolizumab (anti-PD-L1 antibody) in patients with advanced non-squamous NSCLC. Results showed that patients who accepted the atezolizumab and bevacizumab plus chemotherapy had a longer PFS compared with those who accepted bevacizumab plus chemotherapy (8.3 vs 6.8 months, \( P < .0001 \)). Similarly, the ORR was 64% versus 48%.

Much clinical research about PD-1/PD-L1 inhibitors in combination with targeted therapy is being gradually carried out in NSCLC (Table 3).

Combining PD-1/L1 Inhibitors With Other Immunotherapies

CTLA-4 is the earliest discovered immunological checkpoint that is expressed only on T-cells and inhibits T-cell responses when it binds to B7 on antigen-presenting cells. The CTLA-4 inhibitor ipilimumab enhances immune system function by releasing checkpoints and by using antibody-dependent cytotoxicity to eliminate inhibitory T-cells inside the tumor. One clinical IB phase, multicenter study (NCT02000947) showed that different doses of durvalumab plus tremelimumab were administered to 102 patients with NSCLC who had not accepted immunotherapy before enrollment. The median follow-up time was 18.8 weeks; 36% of patients developed AEs, and finally 28% of patients discontinued due to treatment of AEs; 63 patients had an ORR of 17%. The study found that durvalumab (20 mg/kg) + tremelimumab (1 mg/kg) is the maximum dose that can be tolerated. Based on the results of this study, this tolerated dose gradient will be expanded for clinical phase III studies in the future. This clinical trial also concluded that the antitumor effect of the combination does not depend on the degree of PD-L1 expression and might, therefore, provide a new treatment option for those patients with negative PD-L1 expression.

In addition, anti-LAG-3 protein, anti-TIM-3 antibody as well as anti-indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor are novel immune checkpoint blockades. LAG-3 antibodies may reverse T-cell depletion and then activate antitumor immune responses. A preclinical study showed that a single LAG-3 antibody could not restore T-cell function, but combined with the PD-1 inhibitor, it could inhibit the growth of ovarian tumors. TIM-3 and PD-1 are co-expressed in tumor-infiltrating CD8 + T-cells in mice, making it unable to produce interleukin-2 (IL-2), tumor necrosis factor, and interferon-γ. Using these 2 checkpoint inhibitors maximally inhibited tumor growth compared with using one inhibitor alone. IDO1 is highly expressed in a variety of cancers, inhibiting T-cell function through metabolites and then promoting immune escape. Preclinical data supported the hypothesis that blocking IDO1 may be an antitumor strategy. In a number of homologous mouse models, inhibition of IDO1 leads to tumor control.

In brief, based on the results of current immunotherapy research, the combination of most immunotherapy is based on PD-1/PD-L1 inhibitors, so the choice of another immunosuppressant “companion” is particularly important. They selectively act on the TME and tumor-draining lymph nodes to exert synergistic antitumor effects with PD-1/PD-L1 inhibitors.

In conclusion, many combination drug regimens have entered the stage of clinical trials and achieved satisfactory initial results. However, there are still some problems that...
need to be deeply considered. For instance, the mode of combination administration (simultaneous or sequential administration) is particularly important. At the same time, selection of doses in combination therapy and treatment of serious adverse reactions should also be attended to. Patients receiving combination therapy are likely to experience delayed response to treatment, with a process in which the tumor first increases and then becomes smaller. This “pseudoprogression” is determined as disease progression; therefore, it is necessary to discuss and develop new standards to evaluate the effectiveness of the combined therapy.

New Insight: Potential Cancer Therapy With Herbal Extracts or Formulas Related to the Immune System

In the development of traditional Chinese medicine, many effective herbs have been well documented to treat cancers. They have advantages of improving patients’ functional status, clinical symptoms, immune function, and survival rate. At the same time, they induce fewer adverse reactions and are suitable for long-term treatment. To be specific, several herbal extracts mainly focus on treating NSCLC by the immune system. For instance, triptolide, extracted from Tripterygium wilfordii Hook F, inhibits NSCLC by the immune system. For example, triptolide, extracted from Tripterygium wilfordii Hook F, inhibits NSCLC by the immune system. For instance, triptolide, extracted from Tripterygium wilfordii Hook F, inhibits NSCLC by the immune system. For instance, triptolide, extracted from Tripterygium wilfordii Hook F, inhibits NSCLC by the immune system. For instance, triptolide, extracted from Tripterygium wilfordii Hook F, inhibits NSCLC by the immune system. For instance, triptolide, extracted from Tripterygium wilfordii Hook F, inhibits NSCLC by the immune system. For instance, triptolide, extracted from Tripterygium wilfordii Hook F, inhibits NSCLC by the immune system. For instance, triptolide, extracted from Tripterygium wilfordii Hook F, inhibits NSCLC by the immune system. For instance, triptolide, extracted from Tripterygium wilfordii Hook F, inhibits NSCLC by the immune system. For instance, triptolide, extracted from Tripterygium wilfordii Hook F, inhibits NSCLC by the immune system. For instance, triptolide, extracted from Tripterygium wilfordii Hook F, inhibits NSCLC by the immune system. For instance, triptolide, extracted from Tripterygium wilfordii Hook F, inhibits NSCLC by the immune system. For instance, triptolide, extracted from Tripterygium wilfordii Hook F, inhibits NSCLC by the immune system. For instance, triptolide, extracted from Tripterygium wilfordii Hook F, inhibits NSCLC by the immune system.

Related to the immune system

In recent years, there appear more and more advanced technology and novel methods being used to treat NSCLC. First of all, the National Comprehensive Cancer Network guidelines recommend broad-spectrum gene sequencing for patients to detect rare driver mutations and seek to participate in other targeted therapies. In multivariate analysis, patients who receive this technology are more likely to receive immunotherapy. Moreover, the birth of imaging mass cytometry has a profound impact on the research of tumor immunity. We can identify the immune cells in the tumor tissue and know what subgroup they belong to, and also know their location in the tissue, including which cells surround it. More important, the gut microbiota can affect tumor development through a variety of ways: mainly by regulating the host’s innate immune system and increasing DC function to treat tumors; regulating the host metabolism; or directly contacting with tumor tissues. Especially Bifidobacterium in the gut microbiota of mice has anticancer effects and can promote the efficacy of anti-PD-L1 immunotherapy. Besides, network pharmacological studies

Since anti-PD-1/PD-L1 agents have good curative effect on NSCLC patients, some researchers combine them with herbal extracts to study the rate of AEs. For example, combining Viscum album L extracts with ICIs has been studied to evaluate the safety profile of ICIs combined with herb extracts. Although Viscum album L application does not alter ICI-induced AE rates, it is a good attempt that should encourage more research in the future. In a word, the unclear effective components of herbs or compounds and unclear mechanism of action of combination therapy limit the widespread application and promotion of traditional Chinese medicine in the treatment of advanced NSCLC. So, more research needs to be carried out in order to explore new strategies that are both effective and safe.

Conclusion and Perspectives

To sum up, the treatment of lung cancer has a long way to go. And the emergence of immunotherapy, especially checkpoint inhibitors such as PD-1/PD-L1 antibody, has brought good news to patients with advanced NSCLC. But there are still some problems that have to be dealt with. For example, first, we should understand the dosing, frequency, and sequential treatment algorithm to use combination strategies as well as discover other effective combination strategies. It is also significant for us to avoid combinations that lack efficacy and lead to increased toxicity. Second, in addition to biomarkers that we referred above, novel and more precise immune predictive biomarkers are supposed to be found for patient selection. Third, improving the accuracy of combination therapy with detailed analysis of different stages of NSCLC, patients’ age and TME as well as different kinds of metastatic cancers is necessary.

In recent years, there appear more and more advanced technology and novel methods being used to treat NSCLC. First of all, the National Comprehensive Cancer Network guidelines recommend broad-spectrum gene sequencing for patients to detect rare driver mutations and seek to participate in other targeted therapies. In multivariate analysis, patients who receive this technology are more likely to receive immunotherapy. Moreover, the birth of imaging mass cytometry has a profound impact on the research of tumor immunity. We can identify the immune cells in the tumor tissue and know what subgroup they belong to, and also know their location in the tissue, including which cells surround it. More important, the gut microbiota can affect tumor development through a variety of ways: mainly by regulating the host’s innate immune system and increasing DC function to treat tumors; regulating the host metabolism; or directly contacting with tumor tissues. Especially Bifidobacterium in the gut microbiota of mice has anticancer effects and can promote the efficacy of anti-PD-L1 immunotherapy. Besides, network pharmacological studies
discover the mechanism of interference of Chinese compound formula or Chinese herb extracts on the “pathogenic network” from the perspective of overall bioret read balance and then predict the pharmacodynamic active ingredients and multitargets of Chinese herbal medicines to prevent and treat cancers. They may be involved in the regulation of cell signal transduction pathways, potential pharmacological mechanisms, and prescription compatibility. Finally, animal or cell experiments can be done to reveal the modern pharmacological mechanisms of herbal prevention and treatment, and develop new antitumor auxiliary agents. All in all, using novel research methods to treat NSCLC is of great importance and integrating Chinese medicine with Western medicine treatment is a breakthrough point.

Declaration of Conflicting Interests
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work is funded by The Science and Technology Development Fund, Macau SAR (File No. 0096/2018/A3) and The Faculty Research Grant Projects of Macau University of Science and Technology (File No. FRG-19-028-FC).

ORCID iD
Jia-Xin Li https://orcid.org/0000-0002-7489-8840

References
1. Oronsky B, Reid TR, Oronsky A, Carter CA. What’s new in SCLC? A review. Neoplasia. 2017;19:842-847.
2. Khakwani A, Rich AL, Powell HA, et al. Lung cancer survival in England: trends in non–small-cell lung cancer survival over the duration of the National Lung Cancer Audit. Br J Cancer. 2013;109:2058-2065.
3. Zeliadt SB, Sekaran NK, Hu EY, et al. Comparison of demographic characteristics, surgical resection patterns, and survival outcomes for veterans and nonveterans with non–small cell lung cancer in the Pacific Northwest. J Thorac Oncol. 2011;6:1726-1732.
4. Gotwals P, Cameron S, Cipolletta D, et al. Prospects for combining targeted and conventional cancer therapy with immunotherapy. Nat Rev Cancer. 2017;17:286-301.
5. Potters L, Gaspar LE, Kavanagh B, et al. American Society for Therapeutic Radiology and Oncology (ASTRO) and American College of Radiology (ACR) practice guidelines for image-guided radiation therapy (IGRT). Int J Radiat Oncol Biol Phys. 2010;76:319-325.
6. Lazzari C, Karachaliou N, Bulotta A, et al. Combination of immunotherapy with chemotherapy and radiotherapy in lung cancer: is this the beginning of the end for cancer? Ther Adv Med Oncol. 2018;10:175883591876209.
7. Moya-Horno I, Viteri S, Karachaliou N, Rosell R. Combination of immunotherapy with targeted therapies in advanced non–small cell lung cancer (NSCLC). Ther Adv Med Oncol. 2018;10:1758834017745012.
8. Delbaldo C, Michiels S, Syz N, Soria J, Le Chevalier T, Pignon J. Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non–small-cell lung cancer: a meta-analysis. JAMA. 2004;292:470-484.
9. Garon EB, Rizvi NA, Hui R, et al; KEYNOTE-001 Investigators. Pembrolizumab for the treatment of non–small cell lung cancer. N Engl J Med. 2015;372:2018-2028.
10. Scarpace SL. Metastatic squamous cell non–small-cell lung cancer (NSCLC): disrupting the drug treatment paradigm with immunotherapies. Drugs Context. 2015;4:212289.
11. Armand P. Immune checkpoint blockade in hematologic malignancies. Blood. 2015;125:3393-3400.
12. Li XT, Yang JJ, Wu YL, Hou J. Toward innovative combinational immunotherapy: a systems biology perspective. Cancer Treat Rev. 2018;68:1-8.
13. Morgensztern D, Herbst RS. Nivolumab and pembrolizumab for non–small cell lung cancer. Clin Cancer Res. 2016;22:3713-3717.
14. Cyriac G, Gandhi L. Emerging biomarkers for immune checkpoint inhibition in lung cancer. Semin Cancer Biol. 2018;52(pt 2):269-277.
15. Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non–small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387:1540-1550.
16. Jean F, Tomasini P, Barlesi F. Atezolizumab: feasible second-line therapy for patients with non–small cell lung cancer? A review of efficacy, safety and place in therapy. Ther Adv Med Oncol. 2017;9:769-779.
17. Tomasini P, Greillier L, Boyer A, Jeanson A, Barlesi F. Durvalumab after chemoradiotherapy in stage III non–small cell lung cancer. J Thorac Dis. 2018;10(suppl 9):S1032-S1036.
18. Postow MA, Callahan MK, Wolchok JD. Immune checkpoint blockade in cancer therapy. J Clin Oncol. 2015;33:1974-1982.
19. Bianco A, Malapelle U, Rocco D, Perrotta F, Mazzarella G. Targeting immune checkpoints in non small cell lung cancer. Curr Opin Pharmacol. 2018;40:46-50.
20. Shafqat H, Gourdin T, Sion A. Immune-related adverse events are linked with improved progression-free survival in patients receiving anti-PD-1/PD-L1 therapy. Semin Oncol. 2018;45:156-163.
21. Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non–small-cell lung cancer. N Engl J Med. 2015;373:123-135.
22. Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non–small-cell lung cancer. N Engl J Med. 2015;373:1627-1639.
23. Langer CJ, Gadgeel SM, Borghaei H, et al. Carboplatin and pemetrexed with or without pembrolizumab for advanced, nonsquamous non–small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. Lancet Oncol. 2016;17:1497-1508.
24. Reck M, Rodriguez-Abreu D, Robinson AG, et al; KEYNOTE-024 Investigators. Pembrolizumab versus che-
motherapy for PD-L1-positive non–small-cell lung cancer. N Engl J Med. 2016;375:1823-1833.

25. Rittmeyer A, Barlesi F, Waterkamp D, et al. Atezolizumab versus docetaxel in patients with previously treated non–small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet. 2017;389:255-265.

26. Reck M, Socinski MA, Cappuzzo F, et al. Primary PFS and safety analyses of a randomized phase III study of carboplatin + paclitaxel +/- bevacizumab, with or without atezolizumab in 1L non-squamous metastatic NSCLC (IMPOWER150). Ann Oncol. 2017;28(suppl 11):mdx760.002. doi:10.1093/annonc/mdx760.002

27. Barlesi F, Vansteenkiste J, Spigel D, et al. Avlumab versus docetaxel in patients with platinum-treated advanced non–small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study. Lancet Oncol. 2018;19:1468-1479.

28. Dako. PD-L1 IHC 22C3 pharmDx. SK006 50 tests for use with Autostainer Link 48. https://www.accessdata.fda.gov/cdrh_docs/pdf15/P150013S006c.pdf. Published April 2017. Accessed November 6, 2019.

29. Dako. PD-L1 IHC 28-8 pharmDx. SK005 50 tests for use with Autostainer Link 48. https://www.accessdata.fda.gov/cdrh_docs/pdf15/P150025c.pdf. Published October 2015. Accessed November 6, 2019.

30. Hirsch FR, McElhinny A, Stanforth D, et al. PD-L1 immunohistochemistry assays for lung cancer: results from phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project. J Thorac Oncol. 2017;12:208-222.

31. Marchetti A, Barberis M, Franco R, et al. Multicenter comparison of 22C3 PharmDx (Agilent) and SP263 (Ventana) assays to test PD-L1 expression for NSCLC patients to be treated with immune checkpoint inhibitors. J Thorac Oncol. 2017;12:1654-1663.

32. Ventana. Ventana PD-L1 (SP263) Assay. https://www.accessdata.fda.gov/cdrh_docs/pdf16/p160046c.pdf. Published December 28, 2015. Accessed November 6, 2019.

33. Scheel AH, Schäfer SC. Current PD-L1 immunohistochemistry for non-small cell lung cancer. J Thorac Dis Vol. 2018;10:1217-1219.

34. Phillips T, Simmons P, Inzunza HD, et al. Development of an automated PD-L1 immunohistochemistry (IHC) assay for non–small cell lung cancer. Appl Immunohistochem Mol Morphol. 2015;23:541-549.

35. Smith J, Robida MD, Acosta K, et al. Quantitative and qualitative characterization of two PD-L1 clones: SP263 and E1L3N. Diagn Pathol. 2016;11:44.

36. Snyder A, Makarov V, Merghouh T, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 2014;371:2189-2199.

37. Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J. 2015;372:2509-2520.

38. Stewart TJ, Abrams SI. How tumours escape mass destruction. Oncogene. 2008;27:5894-5903.

39. Fumagalli C. Carico mutazionale tumorale: Immunotherapy improves overall survival in several diseases. https://www.aiom.it/wp-content/uploads/2018/07/20180906TO_34_Fumagalli.pdf. Accessed November 6, 2019.

40. Rizvi NA, Hellmann MD, Snyder A, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer. Science. 2015;348:124-128.

41. Carbone DP, Reck M, Paz-Ares L, et al; CheckMate 026 Investigators. First-line nivolumab in stage IV or recurrent non–small-cell lung cancer. N Engl J Med. 2017;376:2415-2426.

42. Watson MMC, Berg M, Soreide K. Prevalence and implications of elevated microsatellite alterations at selected tetranucleotides in cancer. Br J Cancer. 2014;111:823-827.

43. Dudley JC, Lin M, Le DT, Eshleman JR. Microsatellite instability as a biomarker for PD-1 blockade. Clin Cancer Res. 2016;22:813-820.

44. Boland CR, Thibodeau SN, Hamilton SR, et al. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res. 1998;58:5248-5257.

45. Sinicropo FA. The role of microsatellite instability testing in management of colorectal cancer. Clin Adv Hematol Oncol. 2016;14:476-479.

46. Anderson AC, Joller N, Kuchroo VK. Lag-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation. Immunity. 2016;44:989-1004.

47. Ascierto ML, Makohon-Moore A, Lipson EJ, et al. Transcriptional mechanisms of resistance to anti-PD-1 therapy. Clin Cancer Res. 2017;23:3168-3180.

48. Chao T, Furth EE, Vonderheide RH. CXCR2-dependent accumulation of tumor-associated neutrophils regulates T-cell immunity in pancreatic ductal adenocarcinoma. Cancer Immunol Res. 2016;4:968-982.

49. Bach EA, Aguet M, Schreiber RD. The IFN gamma receptor: a paradigm for cytokine receptor signaling. Annu Rev Immunol. 1997;15:563-591.

50. Zaretsky JM, García-Díaz A, Shin DS, et al. Mutations associated with acquired resistance to PD-1 blockade in melanoma. N Engl J Med. 2016;375:819-829.

51. Anagnostou V, Smith KN, Forde PM, et al. Evolution of neoantigen landscape during immune checkpoint blockade in non–small cell lung cancer. JAVELIN Lung 200: an international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res. 2015;75:1468-1479.

52. McGranahan N, Rosenthal R, Hiley CT, et al. Allele-specific HLA loss and immune escape in lung cancer evolution. Cell. 2017;171:1259-1271.e11.

53. Derynck R, Akhurst RJ, Balmain A. TGF-beta signaling in tumor suppression and cancer progression. Nat Genet. 2001;29:117-129.

54. Huang AC, Postow MA, Orlowski RJ, et al. T-cell invigoration to tumour burden ratio associated with anti-PD-1 therapy. J Thorac Oncol. 2017;12:208-222.

55. Vacchelli E, Prada N, Kepp O, Galluzzi L. Current trends in cancer metabolism: combining radiation therapy approaches for lung cancer: combining radiation therapy with targeted and immunotherapies. Transl Lung Cancer Res. 2015;4:545-552.
58. Finkelstein SE, Timmerman R, McBride WH, et al. The confluence of stereotactic ablative radiotherapy and tumor immunology. *Clin Dev Immunol*. 2011;2011:439752.

59. Jindal V, Gupta S. Expected paradigm shift in brain metastases therapy—immune checkpoint inhibitors. *Mol Neurobiol*. 2018;55:7072-7078.

60. Park SS, Dong H, Liu X, et al. PD-1 restrains radiotherapy-induced abscopal effect. *Cancer Immunol Res*. 2015;3:610-619.

61. Shaverdian N, Lisberg AE, Bornazyan K, et al. Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non–small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial. *Lancet Oncol*. 2017;18:895-903.

62. Zitvogel L, Galluzzi L, Smyth MJ, Kroemer G. Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance. *Immunity*. 2013;39:74-88.

63. Apetoh L, Ladoire S, Coukos G, Ghiringhelli F. Combining immunotherapy and anticancer agents: the right path to achieve cancer cure? *Ann Oncol*. 2015;26:1813-1823.

64. Qiao M, Jiang T, Ren S, Zhou C. Combination strategies on the basis of immune checkpoint inhibitors in non–small-cell lung cancer: where do we stand? *Clin Lung Cancer*. 2018;19:1-11.

65. Liu WM, Fowler DW, Smith P, Dalgleish AG. Pre-treatment with chemotherapy can enhance the antigenicity and immunogenicity of tumours by promoting adaptive immune responses. *Br J Cancer*. 2010;102:115-123.

66. Suzuki E, Kapoor V, Jassar AS, Kaiser LR, Albelda SM. Gemcitabine selectively eliminates splenic Gr-1+ /CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. *Clin Cancer Res*. 2005;11:6713-6721.

67. Rizvi NA, Hellmann MD, Brahmer JR, et al. Nivolumab in combination with platinum-based doublet chemotherapy for first-line treatment of advanced non–small-cell lung cancer. *J Clin Oncol*. 2016;34:2969-2979.

68. Liu SV, Camidge DR, Gettinger SN, et al. Atezolizumab (atezo) plus platinum-based chemotherapy (chemo) in non–small cell lung cancer (NSCLC): update from a phase Ib study. *J Clin Oncol*. 2017;35(15 suppl):9092.

69. Antonia S, Goldberg SB, Balmanoukian A, et al. Safety and antitumour activity of durvalumab plus tremelimumab in non–small cell lung cancer: a multicentre, phase 1b study. *Lancet Oncol*. 2016;17:299-308.

70. Siu RL, D'Amato RJ, Kaelin WG, et al. The PTEN pathway is frequently inactivated in human lung cancers and influences clinical responsiveness to angiogenesis inhibition. *Nat Genet*. 2000;26:97-101.

71. Schreck R, Brewster SD, Capon DJ, et al. The EGFR ligand TGF-alpha is a high affinity receptor agonist. *J Biol Chem*. 1987;262:1902-1906.

72. Chua TP, O'Dwyer PJ, O'Shaughnessy J, et al. Prognostic significance of EGFR expression in non–small cell lung cancer (NSCLC). *Clin Cancer Res*. 2005;11:6713-6721.

73. Chen N, Fang W, Zhan J, et al. Upregulation of PD-L1 by EGFR activation mediates the immune escape in EGFR-driven NSCLC: Implication for optional immune targeted therapy for NSCLC patients with EGFR mutation. *J Thorac Oncol*. 2015;10:910-923.

74. Lin K, Cheng J, Yang T, Li Y, Zhu B. EGFR-TKI down-regulates PD-L1 in EGFR mutant NSCLC through inhibiting NF-κB. *Biochem Biophys Res Commun*. 2015;463:95-101.

75. Zhang Z, Yang Y, Wang J, et al. The role of EGFR in the regulation of PD-L1 expression in NSCLC. *Cancer Immunol Res*. 2019;7:963-973.

76. Rizvi NA, Chow LQM, Borghaei H, et al. Safety and response with nivolumab (anti-PD-1; BMS-936558, ONO-4538) plus erlotinib in patients (pts) with epidermal growth factor receptor mutant (EGFR MT) advanced NSCLC. *J Clin Oncol*. 2014;32(15 suppl):8022.

77. Carmelletti P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. *Nature*. 2011;473:298-307.

78. Genetech. Phase III IMpower150 study showed TECENTRIQ (atezolizumab) and Avastin (bevacizumab) plus chemotherapy reduced the risk of disease worsening or death by 38 percent for people with a type of advanced lung cancer. https://www.businesswire.com/news/home/20171206006468/en/Phase-III-IMpower150-Study-Showed-TECENTRIQ-Atezolizumab. Published December 7, 2017. Accessed November 6, 2019.

79. Herzberg B, Campo MJ, Gainor JF. Immune checkpoint inhibitors in non–small cell lung cancer. *Oncologist*. 2017;22:81-88.

80. Antonia S, Goldberg SB, Balmanoukian A, et al. Safety and antitumour activity of durvalumab plus tremelimumab in non–small cell lung cancer: a multicentre, phase 1b study. *Lancet Oncol*. 2016;17:299-308.

81. Siervo M, Romero P, Speiser DE. The CD4-like molecule LAG-3, biology and therapeutic applications. *Expert Opin Ther Targets*. 2011;15:91-101.

82. Matsuzaki J, Gnjatic S, Mhawech-Fauceglia P, et al. Tumor-infiltrating NY-ESO-1–specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer. *Proc Natl Acad Sci U S A*. 2010;107:7875-7880.

83. Melero I, Berman DM, Aznar MA, Korman AJ, Gracia JL, Haenen J. Evolving synergistic combinations of targeted immunotherapies to combat cancer. *Nat Rev Cancer*. 2015;15:457-472.

84. Sakuishi K, Apetoh L, Sullivan JM, Blazar BR, Kuchroo VK, Anderson AC. Targeting Tim-3 and PD-1 pathways to reinstate immune. *Integrative Cancer Therapies*. 2018;55:7072-7078.

85. Beatty GL, O’Dwyer PJ, Clark J, et al. First-in-human phase I study of the oral inhibitor of indoleamine 2,3-dioxygenase-1 (INCB024360) in patients with advanced solid malignancies. *Clin Cancer Res*. 2017;23:3269-3276.

86. Sakuishi K, Apetoh L, Sullivan JM, Blazar BR, Kuchroo VK, Anderson AC. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. *J Exp Med*. 2010;207:2187-2194.

87. Prendergast GC, Smith C, Thomas S, et al. Indoleamine 2,3-dioxygenase pathways of pathogenic inflammation and immune escape in cancer. *Cancer Immunol Immunother*. 2014;63:721-735.

88. Beatty GL, O’Dwyer PJ, Clark J, et al. First-in-human phase I study of the oral inhibitor of indoleamine 2,3-dioxygenase-1 epacadostat (INCB024360) in patients with advanced solid malignancies. *Clin Cancer Res*. 2017;23:3269-3276.

89. Wei J, Yan Y, Chen X, et al. The roles of plant-derived triptolide on non–small cell lung cancer. *Oncol Res*. 2017;27:849-858.

90. Jiang Z, Yang Y, Yang Y, et al. Ginsenoside Rg3 attenuates cisplatin resistance in lung cancer by downregulating PD-L1 and resuming immune. *Biomed Pharmacother*. 2017;96:378-383.

91. Ma J, Liu H, Wang X. Effect of ginseng polysaccharides and ginsenosides on T cells are negatively in infiltrating NY-ESO-1-specific CD8+ T cells in tumor-bearing animals and enhances antitumor immune activity. *Clin Cancer Res*. 2005;11:6713-6721.

92. Prendergast GC, Smith C, Thomas S, et al. Indoleamine 2,3-dioxygenase pathways of pathogenic inflammation and immune escape in cancer. *Cancer Immunol Immunother*. 2014;63:721-735.
88. Guo L, Bai SP, Zhao L, Wang XH. Astragalus polysaccharide injection integrated with vinorelbine and cisplatin for patients with advanced non-small cell lung cancer: effects on quality of life and survival. Med Oncol. 2012;29:1656-1662.
89. Pang L, Han S, Jiao Y, Jiang S, He X, Li P. Bu Fei decoction attenuates the tumor associated macrophage stimulated proliferation, migration, invasion and immunosuppression of non-small cell lung cancer, partially via IL-10 and PD-L1 regulation. Int J Oncol. 2017;51:25-38.
90. Guan J, Dan HU, Hai C. Effect and mechanism of Supplementing Qi and Nourishing Yin decoction on intestinal microbiome of mice with lung carcinoma. Chin Pharm J. 2018;53:1564-1571.
91. Thronicke A, Steele ML, Grah C, Matthes B, Schad F. Clinical safety of combined therapy of immune checkpoint inhibitors and Viscum album L therapy in patients with advanced or metastatic cancer. BMC Complement Altern Med. 2017;17:534.